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Endoplasmic reticulum (ER) malfunction, leading to ER stress, can be a consequence of genome instability and hypoxic tissue
environments. Cancer cells survive by acquiring or enhancing survival mechanisms to counter the effects of ER stress and these
homeostatic responses may be new therapeutic targets. Understanding the links between ER stress and apoptosis may be
approached using drugs specifically to target ER stress responses in cancer cells. The retinoid analogue fenretinide [N-(4-
hydroxyphenyl) retinamide] is a new cancer preventive and chemotherapeutic drug, that induces apoptosis of some cancer cell types
via oxidative stress, accompanied by induction of an ER stress-related transcription factor, GADD153. The aim of this study was to
test the hypothesis that fenretinide induces ER stress in neuroectodermal tumour cells, and to elucidate the role of ER stress
responses in fenretinide-induced apoptosis. The ER stress genes ERdj5, ERp57, GRP78, calreticulin and calnexin were induced in
neuroectodermal tumour cells by fenretinide. In contrast to the apoptosis-inducing chemotherapeutic drugs vincristine and
temozolomide, fenretinide induced the phosphorylation of eIF2a, expression of ATF4 and splicing of XBP-1 mRNA, events that
define ER stress. In these respects, fenretinide displayed properties similar to the ER stress inducer thapsigargin. ER stress responses
were inhibited by antioxidant treatment. Knockdown of ERp57 or ERdj5 by RNA interference in these cells increased the apoptotic
response to fenretinide. These data suggest that downregulating homeostatic ER stress responses may enhance apoptosis induced by
oxidative stress-inducing drugs acting through the ER stress pathway. Therefore, ER-resident proteins such as ERdj5 and ERp57 may
represent novel chemotherapeutic targets.
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Cancer cells acquire survival mechanisms, such as the inactivation
of the p53 gene family (Wyllie et al, 1999), allowing them to
circumvent death as a consequence of DNA damage. Cell death can
also be induced as a result of a stress-signalling pathway activated
by accumulation of misfolded or mutated proteins in the
endoplasmic reticulum (ER) (Rao et al, 2004). Endoplasmic
reticulum stress and the activation of mechanisms to protect cells
against the consequences of ER malfunction are increasingly being
recognised as key concepts in cancer cell biology. As the
accumulation of aberrant proteins in the ER can result from
chromosomal rearrangements during carcinogenesis (Khan et al,
2004), homeostatic responses to prevent or ameliorate the risk of
apoptosis from ER stress may be a significant factor allowing
transformed cells to survive the consequences of genomic
instability. Endoplasmic reticulum stress pathways can also be
activated in tumour cells as a result of hypoxia and other
environmental factors (Feldman et al, 2005; Koshikawa et al,
2006). Shifting the balance between survival and apoptosis in
favour of survival as a result of enhanced (constitutive or induced)
homeostatic ER responses may facilitate metastasis and drug
resistance. For example, it has been shown that the induction of
the unfolded protein ER stress response (UPR) can increase the
resistance of multiple myeloma cells to etoposide (Gray et al,
2005). Although ER stress responses represent homeostatic
mechanisms allowing cells to survive the consequences of
perturbations in the protein folding and processing functions of
the ER, it is not clear how these mechanisms interact with
signalling pathways controlling apoptosis. The point at which
homeostatic mechanisms cannot cope and apoptosis is induced is
critical to understanding the relationships between ER stress and
apoptosis, and how ER stress can be used to increase chemother-
apeutic drug targeting to tumour cells.
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mide] has an increasingly important profile as a cancer preventive
and chemotherapeutic drug (Malone et al, 2003). Unlike most
retinoids, fenretinide induces apoptosis in vitro; the generation of
reactive oxygen species (ROS) is a common feature of fenretinide-
induced apoptosis in many cell types. In SH-SY5Y neuroblastoma
cells, ROS generation is apparently mediated by a ceramide-
ganglioside signalling pathway and leads to induction of the ER
stress-associated transcription factor GADD153/CHOP (Lovat
et al, 2002). Furthermore, fenretinide induces NFkB activity in
these cells and apoptosis is mediated by the NFkB pathway
(Campbell Hewson et al, 2005). As this pathway is also implicated
in ER stress responses, particularly in relation to ER stress-induced
apoptosis of neuronal cells (Chen and Gao, 2002), fenretinide-
induced apoptosis may be accompanied by, or result from, the
activation of ER stress responses. The aim of this study was to test
the hypothesis that fenretinide induces ER stress, and to elucidate
the role of ER stress responses in fenretinide-induced apoptosis.
Although pathways of fenretinide-induced apoptosis have been
relatively well characterised in neuroblastoma cells, melanoma
cells also undergo apoptosis in response to fenretinide (Montaldo
et al, 1999a) and to test the idea that neuroectodermal cells have
similar response pathways, we have studied human neuroblastoma
and melanoma cell lines.
MATERIALS AND METHODS
Cell culture and flow cytometry
Human SH-SY5Y neuroblastoma and A375 and SK-MEL110
melanoma cells were cultured in DMEM containing 4.5gl
 1
glucose and supplemented with 10% foetal bovine serum as
described previously for SH-SY5Y cells (Lovat et al, 2004).
Fenretinide (Janssen-Cilag Ltd, Basserdorf, Switzerland), temozo-
lomide (OSI Pharmaceuticals), vincristine, velcade (Janssen
Pharmaceutica) or thapsigargin (Sigma Chemical Co., St Louis,
MO, USA) were added in ethanol (fenretinide and vincristine) or
DMSO (Lovat et al, 2004), with an equal volume of vehicle used to
treat control cells. The SH-SY5Y cells were treated with fenretinide
at a concentration of 3mM, vincristine at 10nM, velcade at 5nM
or thapsigargin at 1.5mM. The melanoma cell lines were more
resistant to drug-induced apoptosis, and for these cells, fenretinide
was used at final concentrations of 10 or 15mM, as specified in the
results, temozolomide was used at 1mM, velcade at 30nM and
thapsigargin at 7.5mM. In these experiments, thapsigargin was used
as a reference positive control for ER stress responses and
vincristine and temozolomide as negative controls. Velcade was
also used in some experiments as a comparator for fenretinide
responses. The concentrations of fenretinide used were within the
range of IC50 values described previously for a sample of 10 human
melanoma cell lines (Montaldo et al, 1999a). Vitamin C was added
to cells to a final concentration of 100mM as described previously
(Lovat et al, 2000). Flow cytometry of fixed and propidium iodide-
stained cells was used to estimate the level of cell death or
apoptosis, expressed as the percentage of cells which were
hypodiploid (Lovat et al, 2000). The generation of ROS was
detected by staining cells after trypsinization with 10mM 5-(and
–6)-chloromethyl-20,70-dihydrodichlorofluorescein diacetate (CM-
H2DCFDA) or 1mM dihydroethidine (DHE) for 20min at 371Ci n
the dark and evaluated by flow cytometry as previously described
(Lovat et al, 2000, 2002).
Identification of genes induced by fenretinide in SH-SY5Y
cells
Endoplasmic reticulum stress genes induced by fenretinide in
SH-SY5Y cells treated with or without 3mM fenretinide for 6h were
identified from microarray analysis: cells were lysed using Trizol
(Invitrogen Life Technologies, Carlsbad, CA, USA) and total RNA
was extracted according to the manufacturer’s instructions.
Poly(A)þ RNA was isolated by oligo-dT latex bead chromato-
graphy (Qiagen Inc., Valencia, CA, USA). Reverse transcriptase,
primed with poly(dT), was used to synthesize Cy3- and Cy5-
labelled cDNA using the Cyscribe cDNA labelling kit (Amersham
Biosciences UK Ltd, Amersham, UK). Labelled cDNA probes were
hybridised to glass slide micro-arrays containing 24000 genes
(Stanford University, CA, USA) and detected using a Packard
MicroArray scanner (Packard BioScience, Billerica, MA, USA) with
Quant Array software. Experiments were performed in triplicate
and expression confirmed by Western blotting and reverse
transcriptase-polymerase chain reaction (RT-PCR) in separate
experiments.
Western blotting
Total protein was extracted from cell pellets and separated by
electrophoresis through 12% SDS-PAGE gels (30mg per track) and
blotted onto nitrocellulose as described previously (Lovat et al,
2004). Blots were probed with antibodies to GADD153 (Santa Cruz
Biotechnology Inc., Santa Cruz, CA, USA, diluted 1: 1000), ERp57
(Stressgen, Victoria, BC, Canada, diluted 1:5000, and Santa Cruz,
sc-23886, diluted 1:100000), ERdj5 (Abnova Corporation, Taipei,
Taiwan; DNAJC10 polyclonal antibody H00054431-A01, diluted
1:2000), calreticullin (Stressgen, diluted 1:2000), calnexin (Santa
Cruz, diluted 1:1000), GRP78 (Santa Cruz, diluted 1:1000), eIF2a
(Cell Signaling, diluted 1:1000), phosphorylated eIF2a (P-eIF2a;
Cell Signaling, diluted 1:1000) or cleaved caspase-3 (Cell Signalling
Technology, Danvers, MA, USA, diluted 1:1000). As a loading
control, blots were probed with b-tubulin (Sigma, Poole, UK)
diluted 1:5000 (Lovat et al, 2002) or b-actin (Sigma, Poole, UK,
diluted 1:5000). For detection, blots were incubated with
secondary peroxidase-conjugated antibodies (Jackson Immuno-
Research Inc., West Grove, PA, USA, diluted 1:5000, or Upstate
Biotechnology, UK, diluted 1:2000) and visualized using the ECL
Plus system (Amersham Biosciences, UK) (Corazzari et al, 2003).
Reverse transcriptase-polymerase chain reaction
For analysis of XBP-1 splicing, the human XBP-I sequence was
amplified by RT–PCR with the primer pair AAACAGAGTAGCA
GCTCAGACTGC and CCTTCTGGGTAGACCTCTGGGAG (Calfon
and Harding, 2004). RT–PCR was used to quantify ERdj5 and
GAPDH (as a loading control) in RNA extracted from cells treated
with thapsigargin or fenretinide. For these PCR analyses, cells were
lysed and total RNA was extracted with Trizol as above. A poly(dT)
primer (1mM) was used to generate cDNA from 2mg of RNA. The
human ERdj5 sequence was amplified with the primer pair
GCCATTTTAGTGGGCACAGATCAGG and CAGCCAGCCAATAC
CAGCAGCA and the human ERp57 sequence was amplified with
the primer pair ACGTGCTAGAACTCACGGA and ACTGAAGCT
GGTCCTGCCTG. Amplification of human GAPDH sequence was
with the primer pairs GATATCGCCGCGCTCGTCGTCG and
AGGTAGTCAGTCAGGTCCCGGC. The number of cycles used for
each primer pair in the PCR reactions was adjusted so that
amplification remained within an approximately linear range.
Quantification of mRNA by real-time RT–PCR
Total RNA was isolated from cell pellets using the RNeasy Mini kit
(Qiagen, Crawley, UK). RNA was reverse-transcribed using
Promega’s Reverse Transcription System according to the
manufacturer’s instructions, using random hexamer primers. For
human ERdj5 and ERp57, real-time PCR was performed on 20–
40ng cDNA using predesigned TaqMan Gene Expression Assays,
in combination with the TaqMan Universal PCR master mix
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s(Applied Biosystems, Warrington, UK). Appropriate controls for
nonspecific amplification and contamination were included. A
GeneAmp 5700 Sequence Detection System (Applied Biosystems)
was used for real-time PCR amplification. As internal standard,
b-actin was measured simultaneously using the endogenous
control assay provided by Applied Biosystems. Polymerase chian
reaction amplification procedures followed the manufacturer’s
instructions. Briefly, the thermocycling program consisted of one
cycle at 501C for 2min followed by 951C for 10min and 40 cycles at
951C (15s) and 601C (1min). The data were analyzed using the
GeneAmp Sequence Detection System software. For ATF4 mRNA
and mRNA for the ribosomal protein L34 used as an internal
control, primers were designed using Primer Express 1.0 Software
(Applied Biosystems) and amplification was performed using a
LightCycler with DNA Master SYBR Green I kit (Roche Applied
Science, Monza, Italy) as specified by the manufacturer’sinstruc-
tions. Primers for ATF4 were GTGGCCAAGCACTTCAAACC and
CCCGGAGAAGGCATCCTC, and for ribosomal protein L34: GTC
CCGAACCCCTGGTAATAGA and GGCCCTGCTGACATGTTTCTT.
The comparative Ct method (DDCt) was used for relative
quantification of gene expression.
siRNA-mediated knockdown
For both ERdj5 and ERp57, two different siRNAs were evaluated
against a scrambled siRNA control, and at doses of 20 and 40nM
for each siRNA in all cell lines. The siRNA knockdown
experiments were performed by plating 0.25 10
6 cells in six-well
plates overnight and transfecting for 18h with 20 or 40nM (final
concentrations) siRNA using lipofectamine in Optimem culture
medium (Invitrogen) (Lovat et al, 2004). After incubation over-
night at 371C, fetal bovine serum was added to 10% and cells
incubated with or without 3 or 10mM fenretinide for a further 24h.
Replicates were used for analysis of apoptosis and to verify
knockdown by real-time PCR and Western blotting. siRNAs,
supplied desalted and annealed by Eurogentec (Southampton, UK)
were: ERdj5-2 GGAGGAGAUUGUUUGACUU; ERdj5-3 AGACAAG
CUUUCAAGAAAU; ERp57-1 GGACAAGACUGUGGCAUAU; ER
p57-2 GAAGCUAAAUCCAAAGAAA and scrambled nonsilencing
control UUCUCCGAACGUGUCACGU.
Data analysis
Statistical analysis of apoptosis and gene induction in each cell line
was by one-way ANOVA with all pairwise comparisons after
Bonferroni correction. Analysis of gene knockdown experiments
with respect to apoptosis or gene expression as response variables
was by a General Linear Model (GLM) with cell line, fenretinide
treatment and siRNA type as independent factors, and siRNA dose
as a linear effect (linear contrast). Analysis of apoptosis in
response to different ER stress inducers or cytotoxic drugs after
knockdown with control, ERdj5 or ERp57 siRNA was by two-way
ANOVA (drug and siRNA type) with Bonferroni-corrected
hypothesis tests for specific comparisons. Analyses were carried
out using Systat version 10 (Systat Software UK Ltd, London, UK).
Error bars on graphs are 95% confidence intervals, except where
the mean and range of duplicate measurements are shown, as
explained in the legends.
RESULTS
Activation of ER stress responses by fenretinide
To test the hypothesis that fenretinide activates ER stress
responses, a 24K microarray was screened for the induction of
ER stress genes in SH-SY5Y neuroblastoma cells after a 6-h
treatment with fenretinide. In addition to GADD153, four other
genes associated with ER stress were induced greater than twofold:
ERdj5 (an ER-resident protein containing DnaJ and thioredoxin
domains; Cunnea et al, 2003), ERp57 (GRP58; an ER-resident
protein-disulphide isomerise; Frickel et al, 2004), calreticulin and
calnexin (both ER-resident chaperones; Bedard et al, 2005). To
verify the induction of these genes in independent experiments
and to assess their relevance as markers of fenretinide response in
neuroectodermal cells, we studied the activation of these genes in
SH-SY5Y neuroblastoma cells and A375 melanoma cells (Kozlowski
et al, 1984). We have also studied SK-Mel-110 melanoma cells
(Albino et al, 2000), but as the results for these cells were, in all
respects, similar to A375 cells, only data for the A375 cells are
reported here. In addition, as a positive control, we compared the
fenretinide response of these cells with their response to
thapsigargin, a well-characterised inducer of ER stress (Kass and
Orrenius, 1999). Both agents induced apoptosis in these cell lines
(Figure 1); however, as has been reported for other melanoma lines
with respect to fenretinide sensitivity (Montaldo et al, 1999), the
melanoma cells were more resistant than SH-SY5Y cells and
needed three- to five-fold higher concentrations of either agent to
induce comparable levels of cell death. The time course of
fenretinide-induced apoptosis has been published previously
(Lovat et al, 2000); in the experiments reported here, we have
treated cells with fenretinide or other agents to achieve an
apoptotic index of 20–25% to avoid early molecular events in
stress responses being masked by high levels of cell death.
Western blots confirmed the induction of GADD153, ERp57,
calreticulin and calnexin in response to fenretinide or thapsigargin
(Figure 2A). In these experiments, the Western blots were also
probed for GRP78 (Gene Symbol HSPA5, also known as BiP), an
additional ER stress marker (Bertolotti et al, 2000): this was also
induced by fenretinide and thapsigargin (Figure 2A). We initially
used RT–PCR to confirm the induction of ERdj5 mRNA under the
same conditions (Figure 2B). However, subsequent experiments
using real-time quantitative PCR confirmed the induction of ERdj5
and also ERp57 mRNA (see below).
The induction of eIF2a phosphorylation and splicing of XBP-1
mRNA are events used to define ER stress (Brostrom and
Brostrom, 1998; Calfon et al, 2002). Phosphorylation of eIF2a
was induced by thapsigargin (1.5mM for SH-SY5Y cells, 7.5mM for
melanoma cells) within 15min of treatment with fenretinide in
SH-SY5Y cells and within 4h of treatment in A375 cells (Figure 2C).
Under similar conditions, the splicing of XBP-1 mRNA was
induced within 6h of thapsigargin treatment and within 6–18h
after treatment with fenretinide (Figure 2D). To ask if ER stress
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Figure 1 Fenretinide or thapsigargin induced cell death in SH-SY5Y and
A375 cells. Cells were treated with fenretinide at 3mM (SH-SY5Y cells) or
15mM (A375 cells), or thapsigargin at 1.5mM (SH-SY5Y cells) or 7.5mM
(A375 cells) for 24h and cell death (apoptosis) measured by flow
cytometry. Bar heights are mean percentage apoptosis of three
replicatesþ95% confidence interval (error bars).
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sresponses were a general response of these cells to cytotoxic
agents, the cells were treated for up to 24h with vincristine (SH-
SY5Y cells) or temozolomide (A375 cells), cytotoxic agents used
clinically to treat neuroblastoma or melanoma, respectively. In
contrast to fenretinide or thapsigargin, these agents did not induce
detectable XBP-1 splicing up to 24h after treatment (Figure 2D).
Increased expression of the transcription factor ATF4 is also a
characteristic of ER stress responses. Fenretinide induced a three-
fold increase in ATF4 expression after 24h. Although slight
induction was seen in SH-SY5Y cells treated with vincristine for
18h, and in A375 cells treated with temozolomide for 6h, this did
not reach the levels induced in response to fenretinide (Figure 3).
These data indicate that fenretinide induces ER stress in SH-SY5Y
and A375 neuroectodermal tumour cells.
Blocking ROS inhibits the fenretinide-induced ER-stress
response
Previous studies have shown that antioxidants block ROS
induction and apoptosis in response to fenretinide in SH-SY5Y
cells (Lovat et al, 2000, 2002). In SH-SY5Y cells, ROS production
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0
Figure 2 The induction of ER-stress genes in response to fenretinide or thapsigargin in SH-SY5Y and A375 cells. (A) Western blots of total protein
extracted from SH-SY5Y cells (left-hand column) or A375 cells (right-hand column) treated with thapsigargin for 24h (Thap; 1.5mM for SH-SY5Y cells or
7.5mM for A375 cells) or fenretinide (FenR; 3mM for SH-SY5Y cells or 15mM for A375 cells) for 0, 6, 18 or 24h. Blots were probed with antibodies to
GADD153, ERp57, calreticulin, calnexin, GRP78 and, as a loading control, b-tubulin. Apparent molecular weights of the relevant bands are given on the left.
(B) Reverse transcription–polymerase chain reaction was used to quantify ERdj5 and GAPDH (as a loading control) in RNA extracted from cells treated
with thapsigargin or fenretinide. In the PCR reactions the number of cycles used for each primer pair was adjusted so that amplification remained within an
approximately linear range. (C) Western blots (as in A) probed using antibodies for eIF2a and phosphorylated eIF2a (P-eIF2a). Cells were treated with
fenretinide for 0.25, 0.5, 1, 2 or 4h, or thapsigargin for 4h, (D) induction of XBP-1 splicing in response to fenretinide or thapsigargin as in (B) with additional
experiments to show lack of XBP-1 splicing in cells treated with 10nM vincristine (SH-SY5Y cells) or 1mM temozolomide (A375 cells) for up to 24h.
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Figure 3 Induction of ATF4 mRNA in SH-SY5Y cells (upper graph) and
A375 cells (lower graph) in response to treatment with fenretinide (3 or 15mM
respectively) for 24h, or with thapsigargin (1.5mM or 7.5mM, respectively) or
10nM vincristine (SH-SY5Y cells) or 1mM temozolomide (A375 cells) for 6, 18
and 24h. Bar heights and error bars are means and upper range of duplicate
samples or means and upper standard deviation of triplicate samples
(thapsigargin data) relative to the control (vehicle) treatment.
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sreaches a maximum after about 6h of fenretinide treatment (Lovat
et al, 2000). Fenretinide also induces ROS in A375 cells
(Figure 4A). In contrast, ROS was not induced by thapsigargin
in SH-SY5Y or A375 cells (Figure 4A), or by vincristine in SH-
SY5Y cells or temozolomide in A375 cells. Therefore, increased
ROS is not an early event in response to ER stress induced by
thapsigargin, and is not a general response to cytotoxic agents.
Recently, it has been shown that a new anticancer drug, the
proteasome inhibitor velcade (bortezomib, PS-341), induces ER-
stress responses in some cell types (Fribley et al, 2004; Obeng et al,
2006) and which is apparently mediated by ROS induction in
mantle-cell lymphoma cells (Perez-Galan et al, 2006). However,
this drug was also ineffective at inducing ROS in SH-SY5Y or A375
cells after 3–16h of treatment.
The antioxidant vitamin C blocked the induction of ROS in A375
cells in response to fenretinide (Figure 4B, centre panel) and
abrogated fenretinide-induced apoptosis (Figure 4B, right panel).
In SH-SY5Y and A375 cells, vitamin C blocked the fenretinide-
induced increase in GRP78 and ERp57 protein and mRNA for
ERp57 and ERdj5 (Figure 4C and D). In these experiments, the
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smeasurements of ERdj5 and ERp57 mRNA levels by real-time
quantitative PCR show that fenretinide induced a 1.5-2-fold
increase in mRNA levels for these two genes. This is additional
verification of the RT–PCR experiments for ERdj5, and also shows
that the induction of ERp57 protein is a result of increased mRNA
levels. These data suggest that fenretinide induces ER stress in
these cells via the induction of ROS.
Increasing fenretinide-induced cell death by knockdown of
ER-stress-response proteins
Since the induction of ER stress proteins may represent a
homeostatic response to protect the cell from environmental
stress, we predicted that the apoptotic response to fenretinide
would be increased by knockdown of ER stress response proteins.
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Figure 5 SiRNA-mediated knockdown of ERdj5 increased apoptosis in response to fenretinide in SH-SY5Y and A375 cells. In all experiments, SH-SY5Y
cells were treated with fenretinide at 3mM and A375 cells with fenretinide at 10mM. For the A375 cells, a slightly lower concentration of fenretinide was used
to ensure that any increased cell death remained within a 20–80% range. Cell death (apoptosis) was measured by flow cytometry. Two different ERdj5
siRNAs were evaluated against a scrambled siRNA control, and at doses of 20 and 40nM. The upper graphs show the percentage apoptosis of SH-SY5Y
cells (left-hand column) and A375 cells (right-hand column) and the lower graphs show real-time quantitative PCR data to verify ERdj5 knockdown for SH-
SY5Y cells and A375 cells, respectively. Cells were transfected with 20 or 40nM scrambled control siRNA (siRNA control), 20 or 40nM ERdj5-2 siRNA, or
20nM or 40nM ERdj5-3 siRNA, and subsequently treated with (gray bars) or without (black bars) fenretinide. Real-time quantitative PCR data are expressed
relative to the 20nM scrambled siRNA control in the absence of fenretinide. On all graphs, error bars are the upper 95% confidence limits.
Figure 4 Blocking ROS with an antioxidant inhibits fenretinide-induced stress responses in SH-SY5Y and A375 cells. In all experiments, fenretinide was
used at 3mM to treat SH-SY5Y cells and at 10mM to treat A375 cells; vitamin C (100mM) was added to cells 2h before adding fenretinide and incubation
continued in the presence of both reagents for a further 22h. (A) A comparison of ROS induction in response to fenretinide (FenR), thapsigargin (Thap),
vincristine (Vin; SH-SY5Y cells), temozolomide (Temo; A375 cells) or velcade (Vel)in SH-SY5Y cells (left panel) and A375 cells (right panel). ROS levels are
expressed relative to control vehicle treatment and were measured with two different probes for reactive oxygen intermediates: CM-H2DCFDA or DHE in
separate experiments. Bar heights are means plus upper 95% confidence interval of CM- H2DCFDA fluorescence (black bars) or DHE fluorescence (grey
bars) (n¼3, but n¼6 for control and fenretinide-treated cells). ROS was measured after 6h for control, fenretinide, thapsigargin, vincristine or
temozolomide treatments, but for velcade after 3, 5, 7, 12 and 16h using the DHE probe and 6h with CM-H2DCFDA or DHE probes. (B) left and centre
panels: flow cytometry CM- H2DCFDA-fluorescence profiles for SH-SY5Y (included as a positive control) or A375 cells showing the induction of ROS by
fenretinide (FenR) and the reduction in fenretinide-induced ROS in cells after pretreatment with 100mM vitamin C 2h before adding fenretinide
(VitCþFenR). Vitamin C alone (VitC) did not increase ROS above the background control. Ordinate, event counts; abscissa, fluorescence signal intensity
(FL1-H). Right panel: abrogation of fenretinide-induced apoptosis in A375 cells by vitamin C (mean and upper 95% confidence interval of three replicates).
(C) Western blots showing that the fenretinide-induced increase in expression of ERp57 and GRP78 protein in response to fenretinide was inhibited by
pretreatment of SH-SY5Y or A375 cells with vitamin C. (D) The fenretinide-induced increase in ERp57 and ERdj5 mRNA in SH-SY5Y and A375 cells, as
measured by real-time quantitative PCR, was inhibited by pretreatment with vitamin C. Bar heights are means plus 95% confidence limit for triplicates
samples. Contrasts were used within one-way ANOVA to compare relative ERp57 or ERdj5 mRNA levels in cells treated with fenretinide or fenretinide plus
vitamin C; **Po0.01, ***Po0.001. For ERp57 or ERdj5 in SH-SY5Y cells, one-way ANOVA F3,8439, Po0.0001, contrasts: fenretinide versus fenretinide
plus vitamin C F1,84112, Po0.0001. For ERp57 or ERdj5 in A375 cells, one-way ANOVA F3,1246, Pp0.007, contrasts: fenretinide versus fenretinide plus
vitamin C F1,12413, P¼0.003. In A-D, control, vehicle control; vitC, cells treated with 100mM alone; FenR, SH-SY5Y or A375 cells treated with 3mM or
15mM fenretinide, respectively; vitCþFenR, cells pretreated with 100mM vitamin C 2h before adding fenretinide.
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sTo test this hypothesis with respect to the ER-stress chaperones
ERp57 and ERdj5, SH-SY5Y and A375 cells were treated with
fenretinide after siRNA-mediated knockdown of expression of
ERdj5 or ERp57. Real-time quantitative PCR of mRNA extracted
from parallel samples at 24h confirmed that the fenretinide-
induced increase in ERp57 and ERdj5 mRNA levels was
significantly blocked by siRNAs for ERp57 and ERdj5, respectively,
but not by the control siRNA (Figures 5 and 6; Table 1). There was
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Figure 6 SiRNA-mediated knockdown of ERp57 increased apoptosis in response to fenretinide in SH-SY5Y and A375 cells. Experimental details as in the
legend to Figure 6. Cells were transfected with 20 or 40nM scrambled control siRNA (siRNA control), 20 or 40nM ERp57-1 siRNA, or 20 or 40nM ERp57-2
siRNA, and subsequently treated with (gray bars) or without (black bars) fenretinide. Real-time quantitative PCR results to verify ERp57 knockdown are
shown in the lower graphs. The reduction in expression of ERp57 was also evident on Western blots (data not shown) and shown in independent
experiments (Figure 7).
Table 1 Analysis of siRNA knockdown with respect to apoptosis and levels of ERdj5 and ERp57 mRNA levels in three cell lines SH-SY5Y, SK-Mel-110
and A375
Apoptosis:
ERdj5 ERp57
Effect F P F P
Fenretinide (F1,101) 320 o0.0001 647 o0.0001
SiRNA (F2,101) 23.8 o0.0001 40.2 o0.0001
siRNA dose (F1,101) 4.29 0.041 5.5 0.02
Hypothesis tests
Difference between target siRNAs 0.07 0.79 0.107 0.74
Difference between target siRNA and control siRNA 434 o0.0001 457 o0.0001
mRNA levels
Effect F P F P
Fenretinide (F1,101) 15.6 o0.001 15.7 o0.001
SiRNA (F2,101) 113.2 o0.0001 109.8 o0.0001
siRNA dose (F1,101) 0.79 0.38 1.66 0.2
Hypothesis tests:
Difference between target siRNAs 0.03 0.87 1.99 0.16
Difference between target siRNA and control siRNA 4167 o0.0001 4145 o0.0001
Analysis was done using a General Linear Model (GLM) with, as factors, cell line, fenretinide treatment (no fenretinide or single dose as specified in the legends to Figure 5 and 6)
and siRNA type (scrambled control and two different siRNA for both ERdj5 and ERp57); siRNA dose (20 or 40nM) was included as a linear effect. Separate analyses were
performed for ERp57 and ERdj5 with respect to apoptosis and mRNA levels. The table gives the value of the F statistic (degrees of freedom are given for each main effect) and
the associated probability (P) for the ERp57 and Erdj5 GLMs. Differences between cell lines in the context of the analysis are trivial and are not reported in the table below.
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sequences used for each target mRNA, and no differences between
the results for the two doses (20 and 40nM) used (Table 1).
Transfection with these siRNAs and without subsequent fenreti-
nide treatment also reduced ERdj5 (Figure 5) or ERp57 mRNA
levels (Figure 6) to half or less of those in untreated control cells
transfected with the scrambled siRNA.
Under these conditions of ERp57 or ERdj5 knockdown, there
was a two-fold increase in cell death in response to fenretinide
compared to the scrambled siRNA control (Table 1; Figures 5 and
6). As with ERdj5 and ERp57 mRNA levels, there was no difference
in response to the two different target siRNAs used for each of
ERp57 or ERdj5. However, in contrast to the effects of siRNA
knockdown on ERdj5 and ERp57 transcript levels, there was a
significant siRNA dose effect on cell death (0.054P40.01; Table 1)
with the 40nM siRNA concentration producing greater apoptosis
in combination with fenretinide compared to the 20nM concentra-
tion (Figures 5 and 6). Under these conditions of ERp57 or ERdj5
knockdown, there was a two-fold increase in cell death in response
to fenretinide compared to the scrambled siRNA control (Figures 5
and 6).
To ask if knockdown of ERdj5 or ERp57 enhanced the response
to apoptosis induced by other cytotoxic agents, cells were exposed
to fenretinide, velcade, vincristine (SH-SY5Y cells), temozolomide
(A375 cells) or thapsigargin after transfection with the scrambled
siRNA control, ERdj5-3 or ERp57-2 siRNA. Apoptosis was assessed
quantitatively by flow cytometry of PI-stained cells; as a separate
check on interpretation of flow cytometry data, apoptosis was
assessed qualitatively by the appearance of cleaved caspase-3 on
Western blots although this is a less sensitive technique (Figure 7).
To extend qPCR data on the efficiency of mRNA knockdown
(Figures 5 and 6), reduction of ERp57 or ERdj5 protein by ERp57
or ERdj5 siRNA, respectively, was confirmed by Western blotting
(Figure 7). For SH-SY5Y cells, knockdown of ERdj5 significantly
increased apoptosis in response to fenretinide (F1,30¼8.6,
Bonferroni-corrected Po0.05, 8 comparisons), although in this
experiment the effect of ERp57 knockdown was not statistically
significant (P¼0.192; Figure 7). All other drug treatments were
not enhanced significantly by knockdown of ERdj5 or ERp57. In
A375 cells, apoptosis in response to fenretinide or velcade was
significantly enhanced by knockdown of ERdj5 or ERp57
(F1,30473, Po0.0001). However, knockdown of ERdj5 or ERp57
did not significantly enhance apoptosis in response to temozolo-
mide or thapsigargin (F1,30o7.3, Bonferroni-corrected P40.05).
These results show that knockdown of ER stress response proteins
ERdj5 or ERp57 enhances apoptotic responses to some ER stress
inducing agents, although there may be cell specificity in
enhancement with different ER stress inducers.
DISCUSSION
These results show that fenretinide induces characteristics of an
ER stress response in these neuroectodermal tumour cell lines. The
observation that the antioxidant vitamin C inhibited the induction
of ER stress-response genes and inhibited the induction of ROS in
response to fenretinide, suggests that the ER stress response is a
consequence of ROS induced by fenretinide. Downregulating two
of these stress response genes, ERdj5 and ERp57, increased the
amount of cell death in response to fenretinide and this suggests
that these genes were induced as part of a homeostatic response to
alleviate stresses imposed by fenretinide treatment. The nature of
the fenretinide-induced ER stress is not known, but might result
from lipid peroxide free radicals as a result of 12-lipoxygenase
activity (Lovat et al, 2004). Since both GADD153 and NFkB are
induced in SH-SY5Y cells by fenretinide (Lovat et al, 2003;
Campbell Hewson et al, 2005), the ER stress may result from both
UPR and protein overload, since evidence from other cell types
suggests that these can be mediated by distinct signalling pathways
(Pahl, 1999). A fundamental question raised by these studies is
whether fenretinide simultaneously activates distinct proapoptotic
and prosurvival (protection) mechanisms with apoptosis resulting
if the balance is tipped in favour of the proapoptotic pathway.
%
 
a
p
o
p
t
o
s
i
s
0
10
20
30
40
50
Control siRNA ERdj5 siRNA ERp57 siRNA
ctrl
ctrl
ctrl
ctrl
FenR
FenR
FenR
Vel
Vel
Vel
Vin
Temo
Vin
Thap
Thap
ctrl
FenR
Vel
Temo
Thap
ctrl
FenR
Vel
Temo
Thap
ctrl
ctrl
FenR
FenR
Vel
Vel
Temo
Temo
Thap
Thap
ctrl
FenR
Vel
Temo
Thap
Thap
FenR
Vel
Vin
Thap
%
 
a
p
o
p
t
o
s
i
s
0
20
40
60
80
100
Control siRNA ERdj5 siRNA ERp57 siRNA
*
∗∗∗
SH-SY5Y
A375
Actin
Cleaved
Caspase-3
ERp57
ctrl
ctrl
ctrl
FenR
FenR
Vel
Vel
Vin
FenR
Vel
Vin
Vin
Thap
Thap
Thap
ERdj5
Actin
Cleaved
Caspase-3
ERp57
ERdj5
A
B
∗∗∗
∗∗∗
∗∗∗
Figure 7 Apoptosis in SH-SY5Y cells (A) and A375 cells (B) after gene
knockdown with control, ERdj5-2 or ERp57-3 siRNA. Apoptosis in
response to control vehicle, fenretinide (3 or 10mM), velcade (5 or
30nM), vincristine (10nM) or temozolomide (1mM) (SH-SY5Y or A375
cells, respectively), or thapsigargin (1.5mM for SH-SY5Y or 7.5mM for A375
cells) was measured quantitatively by flow cytometry of PI-stained cells; the
detection of cleaved caspase-3 on Western blots (a technique that is less
sensitive than flow cytometry), relative to b-actin as a loading control, was
used as additional verification of apoptosis (upper panels in A and B).
Confirmation of ERp57 and ERdj5 protein knockdown was assessed by
Western blotting. Bar heights indicate the mean with error bars showing
the upper 95% confidence limits. Statistical comparisons were hypothesis
tests (Bonferroni-corrected) from within a two-way ANOVA in which the
effect of siRNA knockdown of ERdj5 or ERp57 was compared with the
scrambled control for that drug treatment; *Po0.05; ***Po0.0001.
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sAlternatively, there may be a temporal separation of protective
mechanisms and proapoptotic signalling, the latter being initiated
as the capacity to protect against ROS-induced damage is
exceeded.
Many ER stress-induced proteins share similarities in structure
or function. ERp57 is a thiol-oxidoreductase chaperone of the
protein disulphide isomerase (PDI) family and can be physically
associated with calnexin and calreticulin (Bedard et al, 2005).
ERdj5 is less well characterized, but in addition to the DnaJ and
thioredoxin domains it is a chaperone that co-localises with PDIs,
has a PDI-like domain and interacts with GRP78 (Cunnea et al,
2003). Thus, the accumulation of unfolded or misfolded proteins
within the ER is likely to result in the induction of proteins to
facilitate an increase in the rate at which such proteins can be
correctly folded and exported. Recent studies have shown that
downregulation of GRP78 increases hepatoma cell toxicity to
troglitazone (Maniratanachote et al, 2005), and downregulation of
ERp57 significantly enhances the neurotoxicity of prions, an ER
stress inducer of neuronal cells (Castilla et al, 2004). Clearly,
downregulating components of homeostatic stress responses, or
interfering with the functions of these proteins, may lead to new
approaches for enhancing the efficacy of drugs that induce
apoptosis of tumour cells via ER stress (Linder and Shoshan,
2005).
The observation that knockdown of ERdj5 or ERp57 enhanced
the extent of cell death induced by fenretinide or velcade adds
considerable support to the view that downregulating ER stress
responses may be therapeutically valuable; the ER resident
proteins ERdj5 and ERp57 may thus be targets for the development
of novel chemotherapeutic strategies. The down-regulation of ER
stress responses may only potentiate cell death induced by certain
classes of therapeutic drugs since the response to DNA-damaging
agents vincristine and temozolomide was not affected by siRNA-
mediated knockdown of ERdj5 or ERp57. These drugs did not
induce responses characteristic of ER stress. Velcade, a drug
currently in clinical trials for haematological malignancies
(particularly multiple myeloma), non-small-cell lung carcinoma
and malignant melanoma (Spano et al, 2005), induces ER stress
possibly as a result of a failure of the 26S proteasome system to
clear unwanted proteins from the ER compartment (Fribley
et al, 2004; Nawrocki et al, 2005; Fribley and Wang, 2006;
Obeng et al, 2006). Although knockdown of ERdj5 or ERp57
increased cell death in response to fenretinide or velcade, these
drugs may induce ER stress via different stress sensors since
velcade, unlike fenretinide, did not induce ROS in SH-SY5Y or
A375 cells. Further studies are needed to elucidate the link
between fenretinide-induced ROS and UPR or protein-overload
mechanisms.
Although ER stress was induced by thapsigargin, cell death in
response to this agent was not affected by knockdown of ERdj5 or
ERp57. Like velcade, thapsigargin did not induce ROS or oxidative
stress in SH-SY5Y cells or A375 cells, and similar results have been
reported for the effect of thapsigargin on leukaemia cells (Zhang
et al, 2006). Thapsigargin disrupts Ca
2þ homeostasis by inhibiting
an ER Ca
2þ-ATPase; although ER stress is a consequence, recent
studies for SH-SY5Y cells and other cell types suggest that
thapsigargin induces cell death by activation of separate ER- and
mitochondria-dependent pathways (Kitamura et al, 2003; Zhang
and Armstrong, 2006). Therefore, the involvement of two separate
death signalling pathways in response to thapsigargin may reduce
sensitivity to down-regulation of ER-stress chaperones, particu-
larly if a mitochondria-dependent mechanism is a major driver of
cell death in response to thapsigargin.
Many existing chemotherapeutic drugs induce DNA or chro-
mosomal damage, leading to cell death via the intrinsic
mitochondrial pathway culminating in the release of cytochrome
c (Kaufmann and Earnshaw, 2000), or by the activation of cell-
surface death receptors. These drugs are relatively indiscriminate,
relying for their success on targeting proliferating cells rather than
tumour cells specifically. In contrast, fenretinide and velcade
appear to be relatively specific for tumour cells (O’Donnell et al,
2002; Fernandez et al, 2005), and we speculate that there may be a
link between this tumour-cell specificity and their ability to induce
ER stress. Clearly, the use of drugs that induce cell death
predominantly via ER-stress, such as fenretinide or velcade, in
combination with agents to reduce homeostatic responses to ER
stress, has the potential to facilitate greater tumour-cell targeting
than is currently possible with conventional chemotherapeutic
drugs.
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